The use of classic psychedelics among adults: a Danish online survey study

References

• Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264–355.
   PubMed Web of Science ®Google Scholar
• Akers BP, Ruiz JF, Piper A, et al. A prehistoric mural in Spain depicting neurotropic psilocybe mushrooms? Econ Bot. 2011;65(2):121–128.
   Web of Science ®Google Scholar
• Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011; 61(3): 364–381
   Google Scholar
• Isbell H, Wolbach AB, Wikler A, et al. Cross tolerance between LSD and psilocybin. Psychopharmacologia. 1961;2:147–159.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897–3902.
   PubMed Web of Science ®Google Scholar
• Kometer M, Schmidt A, Jäncke L, et al. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on oscillations, N170 visual-evoked potentials, and visual hallucinations. Journal of Neuroscience. 2013; 33 (25) 10544–10551.
   Google Scholar
• Preller KH, Herdener M, Pokorny T, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27(3):451–457.
   PubMed Web of Science ®Google Scholar
• Preller KH, Schilbach L, Pokorny T, et al. Role of the 5-HT2A receptor in self- and other-initiated social interaction in lysergic acid diethylamide-induced states: a pharmacological fMRI study. J Neurosci. 2018;38(14):3603–3611.
   PubMed Web of Science ®Google Scholar
• Mason NL, Kuypers KPC, Müller F, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. 2020;45(12):2003–2011.
   PubMed Web of Science ®Google Scholar
• Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019; 44: 1328–1334..
   Google Scholar
• Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268–283.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Richards WA, Johnson MW, et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22(6):621–632.
   PubMed Web of Science ®Google Scholar
• Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4(2):568–572.
   PubMedGoogle Scholar
• Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–1740.
   PubMed Web of Science ®Google Scholar
• Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983–992.
   PubMed Web of Science ®Google Scholar
• Krebs TS, Johansen P. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994–1002.
   PubMed Web of Science ®Google Scholar
• Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014; 202(7): 513–520.
   Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197.
   PubMed Web of Science ®Google Scholar
• Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180.
   PubMed Web of Science ®Google Scholar
• Sanches RF, De Lima Osório F, Santos RGD, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression a SPECT study. J Clin Psychopharmacol. 2016;36(1):77–81.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris R, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619–627.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411.
   PubMed Web of Science ®Google Scholar
• Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481.
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Forcehimes AA, Pommy JA, et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289–299.
   PubMed Web of Science ®Google Scholar
• Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268–1278.
   PubMed Web of Science ®Google Scholar
• Davis AK, Barsuglia JP, Lancelotta R, et al. The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol. 2018;32(7):779–792.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Johnson PS, et al. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J Psychopharmacol. 2017;31(7):841–850.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu A, Davis AK, Erowid F, et al. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol. 2019;33(9):1088–1101.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu A, Davis AK, Erowid E, et al. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psychiatry. 2019;10:955.
   PubMed Web of Science ®Google Scholar
• Uthaug MV, Davis AK, Haas TF, et al. The epidemiology of mescaline use: pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. J Psychopharmacol. 2022;36(3):309–320.
   PubMed Web of Science ®Google Scholar
• Ross S, Fischer S. Psilocybin therapy in advanced cancer – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT05398484?term=psilocybin&type=Intr&phase=23&draw=2&rank=1.
   Google Scholar
• Woolley JD. Psilocybin therapy for depression in bipolar II disorder – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT05065294?term=psilocybin&draw=2&rank=9.
   Google Scholar
• Jensen ME, Fink-Jensen A. Psilocybin-assisted therapy for treatment of alcohol use disorder – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT05416229?term=psilocybin&cond=alcohol&draw=2&rank=1.
   Google Scholar
• Zeifman RJ, Singhal N, Breslow L, et al. On the relationship between classic psychedelics and suicidality: a systematic review; 2021. ACS Pharmacol. Transl. Sci.2021; 4 (2): 436–451.
   Google Scholar
• Hendricks PS, Thorne CB, Clark CB, et al. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29(3):280–288.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Griffiths RR, Hendricks PS, et al. The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology. 2018;142:143–166.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Hendricks PS, Barrett FS, et al. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83–102.
   PubMed Web of Science ®Google Scholar
• Winstock AR, Timmerman C, Davies E, et al. Global Drug Survey (GDS) 2020 psychedelics key findings report; 2021. Available from: https://www.globaldrugsurvey.com/wp-content/uploads/2021/03/GDS2020-Psychedelics-report.pdf.
   Google Scholar
• Johnston LD, Miech RA, O’Malley PM, et al. Monitoring the future national survey results on drug use, 1975–2020: overview, key findings on adolescent drug use. Inst Soc Res. 2021; ED611736: 1–143.
   Google Scholar
• Lipari RN, Park-Lee E. Key substance use and mental health indicators in the United States: results from the 2019 national survey on drug use and health. Substance Abuse and Mental Health Services Administration. 2020; PEP21-07-01-003: 1–156.
   Google Scholar
• Ekholm O, Amalie H, Jensen R, et al. Illegale stoffer Sundheds-og sygelighedsundersøgelsen 2017 Statens Institut for Folkesundhed; 2017. Available from www.sdu.dk/sif.
   Google Scholar
• Saunders JB, Aasland OG, Babor TF, et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption‐II. Addiction. 1993;88(6):791–804.
   PubMed Web of Science ®Google Scholar
• Berman AH, Bergman H, Palmstierna T, et al. Evaluation of the drug use disorders identification test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res. 2005;11(1):22–31.
   PubMed Web of Science ®Google Scholar
• MacLean KA, Leoutsakos JMS, Johnson MW, et al. Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig. 2012;51(4):721–737.
   PubMed Web of Science ®Google Scholar
• Barrett FS, Johnson MW, Griffiths RR. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol. 2015;29(11):1182–1190.
   PubMed Web of Science ®Google Scholar
• Danmarks Statistik. Befolkningens højest fuldførte uddannelse (15-69 år) efter bopaelsområde, herkomst, højest fuldførte uddannelse, alder og køn (AFSLUTTET) – Statistikbanken – data og tal. Available from: https://www.statistikbanken.dk/statbank5a/selectvarval/saveselections.asp.
   Google Scholar
• Ersbøll Ross C. Danskernes Rygevaner 2020 Delrapport 1: Nikotinafhaengighed. Available from: www.sst.dk.
   Google Scholar
• Pedersen CB, Mors O, Bertelsen A, et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 2014;71(5):573–581.
   PubMed Web of Science ®Google Scholar
• Beich A, Gannik D, Saelan H, et al. Screening and brief intervention targeting risky drinkers in Danish general practice–a pragmatic controlled trial. Alcohol Alcohol. 2007;42(6):593–603.
   PubMed Web of Science ®Google Scholar
• Winstock AR, Maier LJ, Zhuparris A, et al. Global Drug Survey (GDS) 2021 key findings report. 2021. Available from: https://www.globaldrugsurvey.com/gds-2022/.
   Google Scholar
• Licht CL, Christoffersen M, Okholm M, et al. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. Hum Psychopharmacol. 2012;27(4):352–363.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Hurwitz ES, Davis AK, et al. Survey of subjective “god encounter experiences”: comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLOS One. 2019;14(4):e0214377.
   PubMed Web of Science ®Google Scholar
• Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016;30(12):1259–1267.
   PubMed Web of Science ®Google Scholar